These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33628109)

  • 1. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
    Yu Y; Qian J; Shen L; Ji W; Lu S
    Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer.
    Thakur S; Rathor A; Jain S; Nambirajan A; Khurana S; Malik PS; Jain D
    J Am Soc Cytopathol; 2024; 13(4):291-302. PubMed ID: 38704351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
    Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
    Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
    Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
    Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma.
    Mahmood K; Jampani P; Clarke JM; Wolf S; Wang X; Wahidi MM; Giovacchini CX; Dorry M; Shofer SL; Shier J; Jones G; Antonia SJ; Nixon AB
    Chest; 2023 Jul; 164(1):252-261. PubMed ID: 36693563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
    Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
    JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
    Song Z; Wang W; Li M; Liu J; Zhang Y
    Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Profiling for Supernatants and Matched Cell Pellets of Pleural Effusions in Non-Small-Cell Lung Cancer.
    Xiang C; Huo M; Ma S; Guo L; Zhao R; Teng H; Zhang J; Han Y
    J Mol Diagn; 2020 Apr; 22(4):513-522. PubMed ID: 32036088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.
    Guo Z; Xie Z; Shi H; Du W; Peng L; Han W; Duan F; Zhang X; Chen M; Duan J; Lin J; Chen X; Lizaso AA; Han-Zhang H; He J; Yin W
    Thorac Cancer; 2019 Apr; 10(4):823-831. PubMed ID: 30779318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
    Yang TM; Leu SW; Li JM; Hung MS; Lin CH; Lin YC; Huang TJ; Tsai YH; Yang CT
    J Cancer Res Clin Oncol; 2009 Jul; 135(7):919-24. PubMed ID: 19085002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pleural effusions for cancer genotyping: A matter of trans-pleural traffic of cell-free tumor DNA.
    Méhes G; Mokánszki A; Tóth L; Csoma SL; Lieber A; Bittner N
    Mol Cell Probes; 2022 Feb; 61():101793. PubMed ID: 35114325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
    Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
    J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
    Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
    Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The study of pleural effusion supernatant cell-free tumor DNA in tumor mutational burden assessment of advanced lung cancer].
    Tong L; Ding N; Li JM; Xu XB; Zhang Y; Ye MS; Li C; Zhang X; Hong QY; Zhou J; Bai CX; Hu J
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Aug; 42(8):596-601. PubMed ID: 31378021
    [No Abstract]   [Full Text] [Related]  

  • 18. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
    Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
    Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study.
    Chang SC; Wei YF; Chen CY; Lai YC; Hu PW; Hung JC; Chang CY
    Mol Diagn Ther; 2024 Nov; 28(6):803-810. PubMed ID: 39147938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.
    Lin J; Gu Y; Du R; Deng M; Lu Y; Ding Y
    Int J Clin Exp Pathol; 2014; 7(12):8813-22. PubMed ID: 25674250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.